Viral kinetics in CoVlD-19outpatients treated with CASIRIVIMAB plus IMDEVIMAB combination

This week's Monday read is from Topics in Antiviral Medicine and Dr. Nidal Huniti, President of Clinical Pharmacology at Amador.

📃 Read it here: https://hubs.la/Q01zNl9m0

Casirivimab and imdevimab (CAS + IMD) is a combination of two neutralizing monoclonal antibodies, administered together, that bind non-overlapping epitopes of the SARS-CoV-2 spike protein receptor binding domain. Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. The CAS + IMD combination was authorized for treatment or post-exposure prophylaxis of COVID-19. Results from previous clinical studies demonstrated that when administered early in COVID-19 patients CAS + IMD combination reduced hospitalization and death by 70%.

This study, carried out by a skilled group of scientists, led by the expert clinical pharmacologist Nidal Al-Huniti, explored the in vivo mechanism of action of the CAS + IMD combination determining the magnitude of antiviral efficacy of various dose regimens when given to COVID-19 outpatients. The study also evaluated the presence of SARS-CoV-2 sero-antibody and ≥1 high-risk factor for developing severe COVID-19 illness as predictors of viral kinetics.

The results indicate that the main mechanism of drug action is blocking de novo infection with an estimated decrease in the infectivity rate of 96.6%, for all dose regimens evaluated in the study. Moreover, all intravenous and subcutaneous dose regimens considered showed similar near to maximal antiviral activity by blocking de novo infection and shortening the time to virus clearance. Overall, the data indicated that the administration of CAS + IMD might be an effective option for the prevention of COVID-19 in specific populations.

Want to learn more?